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Abstract
Background
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Repeated CB1 binding due to THC results in downregulation of the endocannabinoid system in cortex and limbic regions, perhaps disrupting frontolimbic functioning. This is particularly a concern in young adults who are still undergoing neurodevelopment in frontal and
limbic regions. Such disruptions may be linked to increased depressive symptoms, anxiety
symptoms, and executive dysfunction, and decreased behavioral approach.

Objectives
Here we examine the influence of young adult marijuana use on anxiety, depressive symptoms, behavioral approach, and executive dysfunction. The influence of alcohol and gender
were also assessed.
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Methods
84 participants (42 MJ, 42 controls) aged 18–25 were balanced for gender (39 F). Exclusion
criteria included: MRI contraindications, left handed, comorbid Axis-I disorders, major medical or neurologic disorders, prenatal issues, or prenatal alcohol/illicit drug exposure, or
excessive other drug use. Participants completed the FrsBE, BIS/BAS, State-Trait Anxiety
Inventory (State), and BDI-II. Multiple regressions were run to predict anxiety, depressive
symptoms, behavioral approach, and executive dysfunction from MJ group status, past year
alcohol use, gender, and MJ*gender interactions, controlling for cotinine and ecstasy.
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MJ group predicted increased depressive symptoms (p =.049). Decreased fun-seeking
(p =.04), reward response (p =.01), and BAS total (p =.01) were predicted by MJ group.
Gender predicted decreased reward responsiveness in females (p =.049) and decreased
BIS in females (p =.03). Female marijuana users had increased anxiety symptoms (p =.04)
and increased disinhibition (p =.04). Increased cotinine predicted increased drive (p =.046),
reward responsiveness (p =.008) and BAS Total (p =.02). Apathy and Executive Dysfunction were not predicted by any measures. All results had small effect sizes.
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Conclusions/Importance
Depressive symptoms were greater in MJ users, while behavioral approach was decreased.
Cotinine levels predicted increased behavioral approach. Female MJ users also had greater
anxiety and disinhibition. In sum, these findings suggest sub-clinical threshold deficits
related to regular marijuana use that are indicative of a need to prevent marijuana use in
adolescents and young adults.

Introduction
As the most commonly used illicit drug, marijuana is used by 44.4% of 12th graders and over
57.5% of young adults in their lifetime [1, 2]. In general, individuals begin using marijuana
during adolescence, and usage peaks between the ages of 18–25 [3]. Chronic marijuana exposure may result in greater neurocognitive deficits and mood symptoms in this population due
to ongoing neurodevelopment occurring throughout adolescence and emerging adulthood[4].
A decline in the perceived risks associated with marijuana use[5] combined with a recent (past
ten years) doubling of past year marijuana use among young adults (aged 18–29; [6]) emphasizes the importance of understanding the neurocognitive and mood consequences of regular
marijuana use in youth.
The endocannabinoid (eCB) system plays a key neurodevelopmental role [7, 8]). The primary brain cannabinoid receptor, CB1, has significantly greater binding in adolescence than
in adulthood [9], and is activated by delta9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana. This binding modulates the reward system within the ventral
tegmental area (VTA) of the brain, increasing the release of dopamine[10]. Repeated CB1
binding due to exogenous cannabis (THC) exposure results in downregulation of the eCB system [11], particularly in limbic regions, such as the hippocampus (see [12]).
The endogenous eCB system has been implicated in mood symptomatology as well as in
executive functioning deficits [13–15], perhaps due to its concentration of CB1 receptors in
prefrontal and limbic regions [16]. As frontal and limbic neuroanatomy changes during adolescence and into young adulthood [17], so too does the eCB system [7, 18]. It is unsurprising,
then, that marijuana use specifically has been implicated in a rise in executive dysfunction,
anxiety, depressive symptoms, and increased impulsivity in adolescents and emerging adults
in particular [4].
In this sensitive and dynamic neurodevelopmental time period [17], regular (weekly to
daily) marijuana use has been found to have significant neural and functional impact. These
include several neurocognitive deficits, including in attention [19–22], executive functioning
[23–25], and impulsive behavior and inhibition [23, 26–30]. Structural imaging studies have
primarily found abnormalities in frontolimbic regions [31–42]. Given these frontolimbic
abnormalities, it is important to consider the impact of chronic marijuana exposure on mood
and self-reported symptoms of executive dysfunction.
Mood symptoms in the absence of an Axis-I disorder and day-to-day deficits in everyday
executive functioning, as exhibited through behavioral deficits, have been relatively overlooked
in the marijuana literature. This is an important consideration given that traditional neuropsychological measures may not capture every-day dysfunction in substance using populations
[43]. In a longitudinal study by Felton and colleagues [44], self-reported and behavioral measures of disinhibition in 8th grade prospectively predicted increased marijuana use across high
school students, regardless of gender. Self-reported apathy and executive dysfunction on the
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Frontal Systems Behavioral Scale (FrSBe) have also been related to severity of marijuana use
[45]. The most extensive evidence of everyday behavioral deficits comes from self-reported
impulsivity in marijuana users, as measured by the Barratt Impulsivity Scale (BIS-11) with facets of motor function, nonplanning, and attention [27, 37, 46–50]. However, the behavioral
approach and behavioral inhibition aspects of impulsivity have, to our knowledge, only been
investigated in one study, which found no relationship between regular marijuana use and
behavioral approach scores [51]. In investigating mood symptoms and executive dysfunction,
our group has previously reported that in young adult polydrug users, marijuana use significantly predicted anxiety and depressive symptoms, while past year alcohol use predicted executive dysfunction and disinhibition [52]. Consistent with these findings, several other studies
also report increased risk of depressive and anxiety symptoms in regular marijuana users (for
review, see [53]). However, not all studies have found a relationship between marijuana use
and mood (e.g., [23, 28]) or cognitive deficits (e.g., [54]). As there has been limited research
into other facets of impulsivity, such as behavioral approach and avoidance, and particularly
limited investigation into self-reported executive dysfunction, more research is needed in
these areas. Further, as gender and alcohol use are both known to influence impulsivity, mood,
and executive functioning, assessment of their potential moderating impact is needed.
Many of these findings may not be unique to marijuana users. Multiple studies have found
similar executive dysfunction and psychological symptomatology increases in youth with alcohol use disorders and binge drinking histories (see [55]). Marijuana and alcohol are also often
used together simultaneously [56], and both THC and alcohol regulate eCB signaling. While
THC binds directly with CB1 receptors, alcohol interacts indirectly through GABAergic and
glutamatergic neurons [57, 58]. Similar to THC, regular alcohol use also leads to downregulation of CB1 receptors [58]. As both substances act within the eCB system, it is important to
take into consideration how either may be independently affecting function. Therefore, the
current study examines the influence of both alcohol and marijuana use on mood and executive function symptoms.
Finally, an often-important moderator of substance-related psychological symptomatology
and executive functioning is gender. Female marijuana users with a lifetime cannabis use disorder tend to have higher incidence of anxiety or mood disorders than male users with a cannabis use disorder [59], as is also true in the general population [60]. Prefrontal and amygdala
volumes have also been found to differ by gender in marijuana users, with females exhibiting
greater abnormalities which were linked with executive dysfunction and increased depressive
symptoms [39, 41]. One reason for the potential additional susceptibility to the neurotoxic
effects of marijuana may be due to altered signaling in the CB1 receptor in females, but not
males [61, 62]. More widespread effects of THC in adolescent female rats than in male rats
have also been observed [63]. Therefore, when examining consequences of marijuana exposure, it is important to examine potential gender differences.
The present study examined the influence of marijuana use on anxiety, depression, impulsivity, and executive dysfunction. We hypothesized that marijuana use will be predictive of
greater dysfunction and symptoms than healthy controls. Specifically, we predicted that marijuana users would exhibited higher levels of anxiety, depressive symptoms, and executive dysfunction, as well as facets of impulsivity characterized as increased behavioral approach and
decreased behavioral avoidance. As marijuana users often also engage in heavy drinking and
as gender may moderate the effects of marijuana use, the influence of both alcohol and gender
was assessed. It was hypothesized that greater alcohol use would similarly be associated with
increased mood symptoms and decreased executive functioning. Further, it was hypothesized
that gender would influence functioning, such that female users would experience greater
symptoms of functional impairment than male users.
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Materials and Methods
Participants
Eighty-four participants (42 MJ users, 42 controls) were recruited through local newspaper
advertisements and fliers placed around campus at the University of Cincinnati. Groups were
balanced for gender (MJ: 16 female; Controls: 23 female). Inclusion criteria included being a
fluent English speaker 18–25 years old. Participants were considered MJ users if they had
smoked more than 10 times in the past year or more than 500 times lifetime (i.e., either being
a current user or previous heavy user), and had less than 10 other drug uses. Healthy controls
had smoked MJ less than 5 times past year and less than 20 times lifetime. Exclusion criteria
for both groups included: being left handed, MRI contraindications, lifetime history of an
independent Axis-I disorders according to DSM-IV criteria (i.e., the symptoms are not due to
marijuana use), major medical or neurologic disorders, prenatal issues (e.g., gestation <35
weeks) or prenatal alcohol (>4 drinks/day or >7 drinks/week) or illicit drug (>10 uses) exposure, or excessive drug use in lifetime (>10 uses of any drug category except nicotine, alcohol,
or marijuana). Participants were required to remain abstinent from alcohol and drug use for
seven days leading up to the study session, as confirmed through self-report and drug toxicology screen; this time period is typically a long enough period of time for the most substantial
withdrawal symptoms to subside [64].

Procedure
Participants were recruited for the parent imaging genetics study (PI: Lisdahl, 1R03
DA027457). Interested participants called in and were screened using a semi-structured phone
interview for Axis-I disorders according to DSM-IV criteria. If still eligible, participants completed written informed consent and the study protocol in either one or two sessions. Those
with substance use histories completed the psychological questionnaires, drug use interview,
and neuropsychological battery in two sessions (typically 2–3 days apart). Those with minimal
use completed the study in one session. Participants were paid $160 for two sessions ($110 for
one) and received parking reimbursement, local substance treatment resources and images of
their brain. The University of Cincinnati IRB approved all aspects of this study, including the
consent procedure.

Drug Use
Marijuana, alcohol, and other drug use were measured using a modified version of the Timeline Follow-Back (TLFB) [28, 65]. Utilizing memory cues of common holidays and personal
events, participants recounted frequency of drug use over the past year (assessed month-bymonth for one year). Additionally, a semi-structured interview was administered to measure
frequency/quantity of lifetime drug use [28]. For each drug category, participants were asked
their average weekly use for each year of use. The following drug categories were assessed:
ecstasy or Molly, alcohol, marijuana, sedatives (e.g., downers, ketamine, GHB), stimulants
(amphetamine, methamphetamine, cocaine, crack cocaine), hallucinogens (mushrooms, PCP,
LSD, peyote), opioids (heroin, opium), and inhalants (nitrous oxide, paint, glue, household
cleaners, gas). The participant’s drug use was measured in standard units (joints for marijuana;
standard drinks for alcohol; tablets for ecstasy).

Self-Report Symptom Inventories
Anxiety. The State-Trait Anxiety Inventory (STAI; [66]) State subscale measures temporary or
“state” anxiety. Total raw STAI-state was used in the present analysis. Depression. Depression
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was measured by the Beck Depression Inventory—2nd Edition (BDI; [67]). The BDI is a
21-item measure of depressive symptoms over the past 2 weeks. Total raw BDI score was used
in the present analysis. Self-Reported Executive Functioning. Executive functioning in day-today life was measured by the 46-item Frontal Systems Behavioral Scale (FrSBe; [68]). As this
measure was designed to assess daily functioning before and after an acute illness or neurological illness, participants only filled out the “after” portion to report on their current levels of
functioning. Impulsivity/Behavioral Approach. The Behavioral Inhibition System and Behavioral Approach System (BIS/BAS; [69]) is a 30-item inventory measuring approach and avoidance behaviors of moving towards or away from appetitive or unpleasant stimuli, respectively,
with increased BAS and decreased BIS scores being related to increased impulsivity and
response to reward cues, while decreased BAS may be indicative of more apathy and decreased
response to positive reinforcement. The subscales that make up the BAS include reward
responsiveness (anticipation of reward), fun seeking (desire for new and novel positive reinforcers), drive (pursuit of goals), and BAS total (overall happiness and experience of a positive
reinforcer). The BIS does not have subscales, but is one overall score that, when higher, reflects
generally more anxious and punishment-responsive personality traits.

Data analysis
Between-group differences on demographic variables were measured with analyses of variance
(ANOVAs) and χ2 tests; no significant differences between groups emerged, and therefore
demographic variables were not included in subsequent analyses as covariates. The one exception was in gender, which, while it did not differ by groups, was included a priori in the study
aims. All variables were normally distributed, except depressive symptoms and reward
response. These two variables were therefore log transformed to increase normality of distribution. Urine cotinine (NicAlert™, JANT Pharmacal Corporation, Encino, CA, USA), a metabolite of nicotine, was included in all analyses as a covariate, as nicotine withdrawal has been
shown to alter neurocognitive functioning in adolescents in general [70] and in marijuana
users in particular [71], and as past year cigarette use differed by groups. Ecstasy was similarly
included as a covariate, as groups differed in past year ecstasy use. After controlling for potential confounds (i.e., cotinine level, ecstasy), multiple regressions were run to examine whether
marijuana (MJ) group status or alcohol use independently predicted mood or functioning
symptoms. The potential interactive effect of MJ group and gender was also assessed as a second block in the regression. All interpretations of statistical significance were made if p <.05.
Due to power issues, there was no correction for multiple comparisons.

Results
Demographics
Groups did not differ significantly on age [F(1,82) =.04, p =.85], education [F(1,82) = 2.72, p
=.10], reading level (from the WRAT-IV) [F(1,82) = 1.25, p =.27], gender (1 = male, 2 = female)
[x2 = 2.35, p =.13], race (1 = not Hispanic or Latino; 2 = Hispanic or Latino; 3 = unknown)
[x2 = 1.05, p =.31], or ethnicity (1 = American Indian; 2 = Asian; 3 = Native Hawaiian/Pacific
Islander; 4 = Black/African American; 5 = White/Caucasian; 6 = more than one ethnicity)
[x2 = 3.34, p =.50]. See Table 1.

Drug Use Patterns
As would be expected, groups different significantly in drug use patterns, such as cotinine level
[F(1,82) = 26.67, p <.001], past year alcohol use [F(1,82) = 16.97, p <.001], past year marijuana
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Table 1. Demographics by Group.
Controls (n = 42) % or M (SD)+
Range

MJ (n = 42) % or M (SD)+
Range

Age

21.1 (2.2) 18–25

21.2 (2.4) 18–25

Education

13.9 (1.7) 11–18

13.3 (1.8) 9–17

100 (10.5) 78–120

103 (15.1) 73–134

Gender (% female)

55%

38%

% Caucasian

60%

67%

0.1 (.4) 0–2

644 (1272.1) 0–7343

Reading Score (WRAT-IV)

*Past Year Marijuana Use (joints)
*Lifetime Marijuana Use (joints)
*Past Year Alcohol Use (standard
drinks)
*Lifetime Alcohol Use (standard
drinks)
*Past Year Ecstasy Use
*Cotinine Level

1.64 (3.7) 0–15

2483.3 (4937.4) 26–23838

68.2 (91.7) 0–459

330 (400.8) 0–7343

329.93 (519.75) 0–2280

1358.5 (1544.9) 14–6191

0 (0) 0–0

.21 (.6) 0–3

1.21 (2.0) 0–6

3.71 (2.4) 0–6

+

M = mean; SD = standard deviation.
*p <.05
doi:10.1371/journal.pone.0166005.t001

use [F(1,82) = 10.76, p =.002], past year cigarette use [F(1,82) = 5.47, p =.02], and past year
ecstasy use [F(1,82) = 4.63, p =.03].

Clinical Elevations
We examined the percentage of controls and marijuana users who demonstrated clinical elevations on each of the anxiety, depressive and executive function scales (see Table 2), though it is
important to note that no subjects met criteria for current or lifetime psychiatric independent
diagnoses. Seven percent of marijuana users and 2% of controls reached clinical threshold for
depressive symptoms (>14 raw score on the BDI-II; x2(1) =.37, p =.54). In the MJ group, one
individual (2%) reached a clinical threshold of one SD above the mean for anxiety while, in
the control group, 5% of healthy controls reached threshold (T-scores above 60; x2(1) =.40,
p =.54). For self-reported executive functioning, elevations in symptoms were defined as a Tscore above 65. Seventeen percent of marijuana users and 14% of controls were elevated in
their apathy scores (x2(1) =.09, p =.76); 21% of marijuana users and 4% of controls were elevated in their disinhibition scores (x2(1) = 2.28, p =.13); and 36% of marijuana users and 14%
of controls were elevated in their executive dysfunction (x2(1) = 3.94, p =.05).

Primary Analyses
Group Results. MJ group status significantly predicted increased depressive symptoms
[beta =.30, t = 2.00, p =.049, f2 =.055]. On the BIS/BAS, fun-seeking was negatively predicted
by MJ group [beta = -.30, t = -2.10, p =.04, f2 =.06]. Decreased reward response [beta = -.36,
t = -2.55, p =.01, f2 =.09] and decreased BAS System Total were also predicted by MJ group
status [beta = -.38, t = -2.60, p =.01, f2 =.09].
Gender Results. Gender predicted reward response with females having decreased
reward responsivity [beta = -.22, t = -2.00, p =.049, f2 =.10]. BIS System Total was predicted
by gender [beta = -.24, t = -2.18, p =.03, f2 =.065], with females having lower BIS total.
Group Gender Results. MJ group gender use predicted anxiety symptoms [beta =.22,
t = 2.05, p =.044, f2 =.056]. Examination of marginal means revealed that MJ-using females
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Table 2. Clinical Levels of Symptom Scales.
Marijuana Users
M
BDI-II

SD

Range

Controls
Elevated Score*

M

SD

Range

Elevated Score*
2%

6.0

5.6

0–26

7%

4.7

6.7

0–41

STAI-State

43.7

7.4

36–68

2%

42.5

7.3

34–64

5%

Apathy+

53.1

12.8

23–84

17%

53.1

15.0

25–106

14%

Disinhibition+

56.5

12.6

31–100

21%

50.7

12.6

28–84

4%

Exec Dysfunction+

57.9

13.0

21–81

36%

52.1

12.7

31–86

14%

+

Apathy, Disinhibition, and Executive Dysfunction (Exec Dysfunction) are subscales from the Frontal Systems Behavior Scale (FrSBe); normative T-scores

are presented.
*Elevated scores denote the percentage of individuals who demonstrated scores that were greater than 1 SD T-score above the normative group’s mean
on the STAI, above 65 T-score on the FrSBe scales, and raw scores >14 on the BDI-II.
doi:10.1371/journal.pone.0166005.t002

demonstrated increased anxiety symptoms in comparison to males and same-gendered controls (see Fig 1). FrSBe Disinhibition was predicted by MJ gender interactions [beta =.22,
t = 2.07, p =.04, f2 =.11], with female users having greater disinhibition (see Fig 2).
Covariate Results. Cotinine Results. On the BIS/BAS, increased cotinine level predicted increased drive [beta =.27, t = 2.03, p =.046, f2 =.55], increased reward responsiveness [beta =.35, t = 2.70, p =.008, f2 =.053], and increased BAS System Total [beta =.33,
t = 2.50, p =.02, f2 =.085]. Past year alcohol and ecstasy use did not significantly predict any
results.
FrSBe Apathy and Executive Dysfunction were not significantly predicted by any measures.

Fig 1. Anxiety by Group and Gender. Mean STAI State Anxiety raw score by group (left: controls; right: MJ
users) and gender (blue: males; green: females). Results demonstrate that female MJ users have significantly
higher anxiety than same-gendered controls and males.
doi:10.1371/journal.pone.0166005.g001
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Fig 2. Disinhibition by Group and Gender. Mean FrSBe Disinhibition T-score by group (left: controls; right:
MJ users) and gender (blue: males; green: females). Results demonstrate that female MJ users have
significantly higher disinhibition than same-gendered controls and males.
doi:10.1371/journal.pone.0166005.g002

Discussion
The aims of the current study were to assess whether marijuana users demonstrated greater
symptoms of anxiety, depression, and behavioral symptoms of executive dysfunction, while
controlling for the effects of alcohol, cotinine, and ecstasy. Further, we sought to examine
potential gender differences in these effects. Findings suggest that, after one week of abstinence, MJ users exhibited significantly greater depressive symptoms along with decreased funseeking, reward response, and Behavioral Approach Scale total scores. Gender significantly
interacted with marijuana use in predicting anxiety and disinhibition, with females exhibiting
higher levels of anxiety and disinhibition. Apathy and executive dysfunction were also not
related to MJ group status, alcohol use, ecstasy use, and cotinine level often predicted an opposite pattern of BAS scores relative to the marijuana findings.
This study is consistent with prior findings regarding increased depressive symptoms in
marijuana users [52, 72–77]. The eCB system is downregulated in response to repeated THC
binding to CB1 [11], particularly in limbic regions[12], and the eCB system has been linked to
increased mood symptoms [13–15], perhaps suggesting an underlying mechanism. In an independent sample, our group previously reported that increased marijuana use was predictive of
increased depressive symptoms in young adults without independent Axis I mood disorders.
Further, we found that frontolimbic poorer white matter integrity and volume were related to
increased depressive symptoms and apathy in adolescent and young adult MJ users [25, 78].
Marijuana use may therefore lead to white matter abnormalities [25, 78], which in turn may
lead to greater depressive symptoms. A recent meta-analysis has also reported that marijuana
use increases the odds ratio of developing depression [74]. Importantly, the present study
excluded for independent mood disorders, so these findings may not generalize to youth
who develop depression prior to their onset of marijuana use. In addition, the effect size demonstrated was small, indicating that the relationship between marijuana use and depressive
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symptoms maybe subtle. More longitudinal studies are needed to assess the impact of marijuana use on the trajectory of mood symptoms and to establish causality.
Interestingly, the marijuana users in the present sample demonstrated decreased behavioral
approach scores (BAS), a measure of response to rewarding events that is also thought to
reflect aspects of impulsivity. Admittedly few studies have examined impulsivity in marijuana
users with the BIS/BAS. One known study [51] found that increased BAS score was associated
with lifetime experimentation, but not regular use, of marijuana, perhaps suggesting such
appetitive desires are linked to novelty-seeking experimentation but not long-term behaviors;
they further found increased BIS scores being related to transitioning into regular marijuana
use, while our study found no relationship between marijuana and BIS total. In its initial validation, Carver and White [69] suggested that the BAS scale may not be reflective of impulsivity, per se, but of response to reward cues. Other research has suggested the BAS as a measure
of positive or adaptive functioning [79]. Such decreased response to reward, fun seeking, and
overall BAS, though at a small effect size in the present results, may therefore be more indicative of increased apathy and decreased mood, rather than impulsive traits. Indeed, mood disorders have previously been associated with decreased appetitive behaviors as measured by the
BIS/BAS [80, 81]. Increased white matter integrity has also been positively correlated with BAS
subscales in healthy adults [82]. Therefore, as our sample of marijuana users had greater
depressive symptoms and as marijuana use has previously been linked to decreased white matter integrity and volume in frontolimbic regions [25, 34, 83], these findings may reflect more
depressive symptomatology rather than classically defined impulsivity.
The present results indicate that female MJ users had increased anxiety and disinhibition
compared to MJ-using males and non-using females. Females in general show higher rates of
anxiety, although in this study only the MJ-using females demonstrated an elevation in anxiety.
This is consistent with a previous study[59] has shown that females with cannabis use disorder
have a higher incidence rate of mood and anxiety disorders, but these findings are the first to
find these relationships in self-reported symptomatology. Brain regions involved with emotion
identification demonstrate altered connectivity in young cannabis users [84, 85], which may
account for difficulties identifying emotions and higher rates of experienced anxiety [86].
While gender findings are not always consistent, a growing body of literature suggests that
female marijuana users may be more susceptible to marijuana-related emotional dysregulation.
Females have previously been shown to exhibit greater executive dysfunction and depressive
symptoms as predicted by aberrant prefrontal and amygdala volumes [39, 41]. Therefore, there
is increasing evidence that females may be more susceptible to both underlying neurological
deficits as well as anxiety and executive dysfunction deficits and should continue to be considered as a potentially important, though often subtle, factor in the neurocognitive effects of marijuana use.
Self-reported executive dysfunction was generally not statistically related to marijuana use
and marijuana users did not differ significantly from controls in percentage of participants
with elevations. This is in contrast to prior findings of increased self-reported executive dysfunction, apathy, and disinhibition predicting increased marijuana use [44, 45]. One reason
for the lack of difference may be due to the fact that we controlled for alcohol use; while we did
so in our group’s previous study [52], these inconsistent results may be due to the extent of
combined use, or due to different characteristics of samples. Even so, the percentage of MJ
users demonstrating clinical elevations is actually higher than our previous report [52]: apathy
(previous study: 29%; current study: 35%), disinhibition (previous study: 18%; current study:
31%), and executive dysfunction (previous study: 12%; current study: 43%). Such elevations
are consistent with previous studies of self-reported apathy in regular marijuana users and disinhibition as a predictor of later consumption of MJ in young adolescents [44, 87]. In the
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present study, the majority of participants did not meet clinical thresholds for anxiety and
depression, even within the marijuana group, but given the immense cost of mental health
burden [88], any elevations are of concern and highlight the need for prevention of both marijuana use and early intervention for general mental health issues in adolescents. Further, as
Risher and colleagues[89] point out, as cognitive, and we would argue emotional, functioning
are such key aspects of human functioning, a change of even 5% in these domains may be a
red flag for further consideration. Given the relative elevations in symptomatology demonstrated by the present sample, findings look beyond pure statistical significance at even low levels of symptomatology as this may alter the lived experience of the individual. Particularly
when considering the limitations of statistical significance [90], it is suggested that even subthreshold symptoms need to be considered as a potential issue in substance using adolescents
and young adults.
The largely non-significant findings regarding the influence of alcohol use on psychiatric
symptoms and executive dysfunction were in contrast with our hypotheses. Indeed, a number
of studies have previously found heavy and binge drinking to be related to such deficits (see
[55]). For example, Winward and colleagues [91] found that heavy episodic drinking adolescents had a range in executive function deficits in comparison to controls, such as in inhibition
and cognitive switching. Others found that daily mood and anxiety fluctuations predict daily
alcohol consumption in college students [92], and that mood and anxiety disorders increase
the odds ratio of developing an alcohol use disorder [93]. Bekman and colleagues [94] found
initial increased depressive and anxiety symptoms in recently abstinent heavy drinking adolescents, though affect improved after four-to-six weeks of monitored abstinence. However,
given the known microstructural and neural changes that occur with alcohol use in adolescence ([95]; see[96]), perhaps the full deficits related to alcohol have not yet been manifested
but, as Fleming and colleagues [97] suggest, a different mechanism has potentially been
“locked-in” due to alcohol use during this vulnerable developmental time period, which may
lead to larger deficits under the right circumstances in later life (such as in response to a significant stressor). It is also possible that there is a non-linear relationship such that light users
may have fewer symptoms compared to non-users and heavy users. While not investigated
here, future studies may need to address this.
Results suggest an opposite pattern of results found between marijuana use and cotinine
levels in a measure of reward response and impulsivity, with marijuana use predicting
decreased behavioral approach and cotinine level predicting increased behavioral approach.
Given that the BAS subscales and total scales are measures of approach toward appetitive stimuli as well as theorized to be related to increased positive feelings [69], perhaps these results
indicate recent use of tobacco products increases an individuals’ reward sensitivity and enjoyment of activities, at least on the short term. As marijuana users who co-use nicotine have
been shown to have different brain-behavior relationships [98], greater consideration of the
interactive influence of tobacco, in addition to alcohol as argued previously, is needed in future
studies.
As with all studies, limitations should be noted. The sample size, while consistent with
many studies in the literature, was nonetheless small, and should be replicated with more participants. This study was cross-sectional, and therefore more longitudinal studies are needed
to determine causality. This is especially true given that potential bidirectional relationships
exist, with marijuana use leading to increased symptomatology [74, 99], as well as some evidence for adolescent and young adult anxiety and mood symptoms leading to subsequent
marijuana use [100, 101]. However, the exclusion of independent Axis I disorders prior to
marijuana initiation or during marijuana abstinence suggests that these mood findings are not
influenced by comorbid factors. This exclusion criteria may also underestimate the mood
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symptoms seen in comorbid marijuana and major depressive disorder patients, limiting the
generalizability of the findings as other samples may demonstrate higher levels of marijuana
use but have comorbid diagnoses. Clinically, MJ users may be demonstrating greater depressive symptoms, lowered drive, and greater apathy, and these factors need to be considered as
potential treatment targets. MJ using participants may have been experiencing withdrawal
symptoms that influenced their self-reported mood and executive functioning. However,
seven days of abstinence was required, which is typically a long enough period of time for the
most substantial withdrawal symptoms to subside and, in fact, mood does not appear to
change significantly with withdrawal [64]. Finally, given the fact that the majority of participants were Caucasian, these results may not be generalizable to racial minorities; differences in
mood and apathy in marijuana using minorities should be investigated in the future.
Future research is needed to understand the underlying mechanisms of the present findings. For example, greater understanding of underlying neurobiological mechanisms of frontolimbic functioning is needed, such as particular genotypes that may influence the endogenous
endocannabinoid system (e.g., FAAH; [78]) or the downregulation of CB1 signaling [62]. As
discussed previously, both marijuana and alcohol act on the endocannabinoid system and
their effects may be altered by co-occurring use, and though the potential effect of co-occurring
episodic use was not measured in the present study, future research should investigate the
potential influence of simultaneous substance use.
In sum, the present study found behavioral deficits in mood, anxiety, and behavioral
approach (drive, fun seeking, reward sensitivity) symptoms in marijuana users in comparison
to healthy controls after a minimum of seven days of abstinence. We also found increased anxiety and disinhibition in female marijuana users. As no participants met criteria for an independent Axis I disorder, these findings suggest sub-clinical threshold deficits related to regular
marijuana use provide additional evidence for increased prevention efforts in youth. Future
research should assess potential methods of intervention that target frontolimbic function in
young marijuana users.

Supporting Information
S1 Data. The supporting information file includes all data from the present analyses, as
required by PLOSOne.
(XLSX)

Acknowledgments
This work was supported in part by the National Institute of Drug Abuse grant RO3
DA027457. Dr. Lisdahl was also funded by National Institute of Drug Abuse (R01 DA030354)
during manuscript preparation. The funding sources had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions
Conceptualization: KML NEW.
Data curation: NEW DS KML.
Formal analysis: NEW KML DS.
Funding acquisition: KML.
Investigation: KML.

PLOS ONE | DOI:10.1371/journal.pone.0166005 November 11, 2016

11 / 17

Marijuana Use, Behavioral Approach, and Depressive Symptoms in Emerging Adults

Methodology: KML.
Project administration: KML.
Resources: KML.
Supervision: KML.
Visualization: NEW KML DS.
Writing – original draft: NEW.
Writing – review & editing: NEW DS KML.

References
1.

Johnston LD, O’Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the Future national
survey results on drug use: 1975–2014: Overview, key findings on adolescent drug use. In: Michigan
TUo, editor. Institute for Social Research. Ann Arbor2015.

2.

Miech RA, Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national
survey results on drug use, 1975–2014: Volume I Secondary school students. In: Uo Michigan, editor.
Institute for Social Research. Ann Arbor2015.

3.

Degenhardt L, Chiu WT, Sampson N, Kessler RC, Anthony JC, Angermeyer M, et al. Toward a global
view of alcohol, tobacco, cannabis, and cocaine use: Findings from the WHO World Mental Health
Survey. PLOS Medicine. 2008; 5(7):e141. doi: 10.1371/journal.pmed.0050141 PMID: 18597549

4.

Lisdahl KM, Wright NE, Kirchner-Medina C, Maple KE, Shollenbarger S.: The Effects of Regular Cannabis Use on Neurocognition in Adolescents and Young Adults. Curr Addict Rep. 2014; 1(2):144–56.
doi: 10.1007/s40429-014-0019-6 PMID: 25013751; PubMed Central PMCID: PMCPMC4084860.

5.

Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future national survey
results on drug use, 1975–2012: Volume 1, Secondary school students. In: Uo Michigan, editor. Institute for Social Research. Ann Arbor2013.

6.
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